<DOC>
	<DOCNO>NCT01759303</DOCNO>
	<brief_summary>The purpose study determine 4-month Progression-Free Survival ( PFS ) , demonstrate increase tumor double time , eligible subject treat pazopanib accord RECIST version 1.1 guideline .</brief_summary>
	<brief_title>Study Pazopanib Treatment Osteosarcoma Metastatic Lung</brief_title>
	<detailed_description />
	<mesh_term>Osteosarcoma</mesh_term>
	<criteria>Written inform consent assent Age &gt; = 16 year Histologically confirm diagnosis osteosarcoma lung metastasis , progress prior line therapy , relapse Ineligible curative pulmonary metastasectomy Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 guideline . At least one measurable lesion must lungs . Eligible subject require &gt; = 1 line multiagent chemotherapy either neoadjuvantly adjuvantly . Subjects may 02 line therapy metastatic disease . Measured cardiac ejection fraction &gt; = 50 % institutional low limit normal echocardiogram MUGA scan . Adequate organ system function . Females must either nonchild bear potential negative pregnancy test within 3 5 day prior first dose study drug . Children care custody biological parent , adoptive parent , appoint legal guardian , legally appoint foster care . Prior exposure VEGFR tyrosine kinase inhibitor ( small molecule antibody ) VEGFR antibody . Prior malignancy . Note : Subjects another malignancy diseasefree 3 year , subject history completely resect nonmelanomatous skin carcinoma successfully treat situ carcinoma eligible . History clinical evidence central nervous system ( CNS ) metastases leptomeningeal carcinomatosis , unless previously treat , asymptomatic , steroids antiseizure medication 6 month prior first dose study drug Clinically significant gastrointestinal abnormality may increase risk gastrointestinal bleeding . Clinically significant gastrointestinal abnormality may affect absorption investigational product . Presence uncontrolled infection . Corrected QT interval ( QTc ) &gt; 480 msec use Bazett 's formula . History certain cardiovascular condition within past 6 month . Class IIIV congestive heart failure , define New York Heart Association Poorly control hypertension [ define systolic blood pressure ( SBP ) ≥ 140 mmHg diastolic blood pressure ( DBP ) ≥ 90mmHg ] . History cerebrovascular accident include transient ischemic attack ( TIA ) , pulmonary embolism untreated deep venous thrombosis ( DVT ) within past 6 month . Prior major surgery trauma within 28 day prior protocolmandated 4week drug holiday and/or presence nonhealing wound , fracture , ulcer . Evidence active bleeding bleed diathesis . Known endobronchial lesion and/or lesion infiltrate major pulmonary vessel increase risk pulmonary hemorrhage . Hemoptysis red blood excess 2.5 mL ( one half teaspoon ) within 8 week first dose study drug . Any serious and/or unstable preexist medical , psychiatric , condition could interfere subject 's safety , provision inform consent/assent , compliance study procedure . Unable unwilling discontinue use prohibit medication least 14 day five halflives drug , whichever longer , prior first dose study drug duration study treatment . Radiation therapy , minor surgery , tumor embolization , chemotherapy , immunotherapy , biologic therapy , investigational therapy hormonal therapy within 14 day prior protocolmandated 4week drug holiday . Administration nononcologic investigational drug within 30 day five halflives ( whichever longer ) prior protocolmandated 4week drug holiday . Any ongoing toxicity prior anticancer therapy &gt; Grade 1 and/or progress severity , except alopecia . Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate pazopanib excipients contraindicate participation . An untreated tumor growth rate &lt; 6.1 % Screening period may exclude patient .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>